Our Science – Greten Website
Tim F. Greten, M.D.
Dr. Greten received his basic research training at the Department of Biochemistry at The Leopold Franzens University Innsbruck Austria, where he was working on DNA repair mechanisms. He received his first postdoctoral training in lab of Stefan Endres at the University of Munich, where he was working on pharmacological inhibition of cytokine production in macrophages and monocytes. In 1995 Dr. Greten received a postdoctoral fellowship by the German Research Association and developed a new method for the identification of antigen-specific CD8+ T cells using MHC-IgG dimeric molecules in the laboratory of Dr. Drew Pardoll and Liz Jaffee in collaboration with Dr. Jonathan Schneck, at Johns Hopkins Medical School, where he also initiated his first studies on the effect of tumor cell death on tumor specific immune responses. Back in Germany Dr. Greten started his own laboratory as a principal investigator at the Medical School in Hannover, Germany in 1999. He received continuous funding from the German Research Association (DFG) as well as the Helmholtz Society and the Association for International Cancer Research (AICR). His major research interest has been the effect of tumor development and tumor-specific treatment on immune response in cancer patients. In addition, his group is interested in identification of tumor suppressor mechanisms with a special focus on new pathways to target these inhibitory mechanisms. His research is currently focused on investigating the role of myeloid derived suppressor cells (MDSC). MDSC occur during acute and chronic inflammation and are potent suppressors of the adaptive and innate immune system. Therefore these cells play an important role in the context of inflammation related tumor development. Dr. Greten's laboratory is currently investigating the role of MDSC, both in murine models of inflammation and cancer as well as in humans with cancer.
This page was last updated on 12/2/2013.